UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported): August 3, 2004

 

BRUKER BIOSCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-30833

 

04-3110160

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

40 Manning Road
Billerica, MA 01821

(Address of principal executive offices)(Zip Code)

 

 

 

 

 

Registrant’s telephone number, including area code: (978) 663-3660

 

 



 

Item 12.     Results of Operations and Financial Condition

 

On August 3, 2004, Bruker BioSciences Corporation held a conference call to discuss its results of operations for the three and six months ended June 30, 2004. A copy of the conference call transcript is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

 

The information provided in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER BIOSCIENCES CORPORATION
(Registrant)

 

 

Date: August  10, 2004

By:

/s/ Laura Francis

 

 

 

Laura Francis
Chief Financial Officer and Treasurer

 

 

3



 

Exhibit Index

 

Number

 

Description

99.1

 

Bruker BioSciences Corporation transcript of August 3, 2004 conference call.

 

4